BMY250117P57000
- 0.57
- 0.000.00%
Bristol-Myers Squibb Newsroom
Citi Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $65
Bristol-Myers Squibb Analyst Ratings
Morgan Stanley Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating, Maintains Target Price $39
Cautious Outlook on Bristol-Myers Squibb: Sell Rating Maintained Amid Revenue Declines and Financial Challenges
Buy Rating for Bristol-Myers Squibb Driven by Cobenfy's Strong Sales Momentum and Growth Potential
TD Cowen Adjusts Price Target on Bristol-Myers Squibb to $64 From $59
Jefferies Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Maintains Target Price $70
Jefferies Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Maintains Target Price $70
Bernstein Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $62
Bernstein Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)
Redburn Atlantic Adjusts Price Target on Bristol-Myers Squibb to $52 From $53, Maintains Neutral Rating
Bristol-Myers Squibb Analyst Ratings
Truist Securities Maintains Buy on Bristol-Myers Squibb, Raises Price Target to $65
Truist Financial Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Announces Target Price $65
Jefferies Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Maintains Target Price $70
Jefferies Reaffirms Their Buy Rating on Bristol-Myers Squibb (BMY)
Bernstein Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $62
Bernstein Sticks to Its Hold Rating for Bristol-Myers Squibb (BMY)
J.P. Morgan Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Raises Target Price to $70
Bristol-Myers Squibb Analyst Ratings